Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Multi-center, Open, Single-arm Phase I/II Clinical Study of Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 Injection in Chinese Patients With Relapsed/Refractory Lymphoma

NCT05189093 is registered in ClinicalTrials.gov with Hangzhou Hanx Biopharmaceuticals, Ltd. as lead sponsor.

NCT NCT05189093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05189093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Multi-center, Open, Single-arm Phase I/II Clinical Study of Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 Injection in Chinese Patients With Relapsed/Refractory Lymphoma
Lead sponsor
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2021
Completion date
December 31, 2025
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory lymphoma